Protagonist Therapeutics (PTGX) Competitors $64.56 -0.26 (-0.41%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. SMMT, ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, and VRNAShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), Qiagen (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences Qiagen Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Which has more volatility and risk, SMMT or PTGX? Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Is SMMT or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Summit Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 8.12% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% Protagonist Therapeutics 24.88%8.12%7.41% Does the media favor SMMT or PTGX? In the previous week, Summit Therapeutics had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Summit Therapeutics and 3 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.41 beat Summit Therapeutics' score of 0.51 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in SMMT or PTGX? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer SMMT or PTGX? Summit Therapeutics currently has a consensus target price of $31.29, indicating a potential upside of 43.30%. Protagonist Therapeutics has a consensus target price of $68.36, indicating a potential upside of 5.89%. Given Summit Therapeutics' higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 5 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.44Protagonist Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has preferable valuation and earnings, SMMT or PTGX? Protagonist Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit TherapeuticsN/AN/A-$221.32M-$1.01-21.62Protagonist Therapeutics$434.43M9.25$275.19M$0.7092.23 SummaryProtagonist Therapeutics beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.03B$3.34B$6.11B$10.62BDividend YieldN/A2.28%5.66%4.70%P/E Ratio92.5422.1285.7127.13Price / Sales9.25265.70527.78206.21Price / Cash14.3546.3226.3031.12Price / Book5.709.9612.886.68Net Income$275.19M-$52.35M$3.30B$275.95M7 Day Performance-0.88%5.89%4.28%3.24%1 Month Performance6.66%11.54%7.57%10.67%1 Year Performance45.51%24.98%75.50%33.82% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.0052 of 5 stars$64.56-0.4%$68.36+5.9%+46.1%$4.03B$434.43M92.54120Positive NewsSMMTSummit Therapeutics3.0487 of 5 stars$21.43+2.7%$31.29+46.0%+12.3%$15.92BN/A-21.22110ASNDAscendis Pharma A/S2.9956 of 5 stars$204.05+1.5%$244.36+19.8%+43.0%$12.57B$393.54M-39.541,017VTRSViatris1.1631 of 5 stars$10.19+0.8%$10.40+2.1%-12.1%$11.88B$14.74B-3.5132,000RDYDr. Reddy's Laboratories3.2826 of 5 stars$14.17+0.7%$16.95+19.7%-9.5%$11.83B$334.26B21.4627,811Positive NewsMRNAModerna4.3419 of 5 stars$28.49+0.4%$41.81+46.8%-52.7%$11.08B$3.24B-3.785,800ROIVRoivant Sciences3.4279 of 5 stars$16.17+1.2%$19.94+23.3%+42.1%$11.04B$23.23M-23.10860QGENQiagen4.4621 of 5 stars$46.83+1.3%$49.40+5.5%+10.5%$10.41B$1.98B27.675,765Analyst DowngradeELANElanco Animal Health2.5065 of 5 stars$20.65+0.9%$18.33-11.2%+40.8%$10.26B$4.44B24.019,000BBIOBridgeBio Pharma4.1948 of 5 stars$52.86-0.8%$63.94+21.0%+109.5%$10.11B$221.90M-12.92400VRNAVerona Pharma PLC American Depositary Share1.9284 of 5 stars$106.790.0%$109.00+2.1%+233.6%$9.20B$42.28M-107.8730Positive News Related Companies and Tools Related Companies Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Roivant Sciences Alternatives Qiagen Alternatives Elanco Animal Health Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
